丝裂霉素-长春地辛联合化疗作为转移性乳腺癌挽救治疗的失败情况。
Failure of mitomycin-vindesine combination chemotherapy as salvage treatment for metastatic breast cancer.
作者信息
Ardizzoni A, Pronzato P, Canobbio L, Lionetto R, Rosso R
出版信息
J Cancer Res Clin Oncol. 1985;110(1):77-8. doi: 10.1007/BF00402506.
Abstract
Mitomycin plus vindesine have been utilized as salvage therapy in metastatic breast cancer patients refractory to first line chemotherapy. No response was observed in 15 consecutively evaluable patients; according to the Gehan test a lack of effectiveness of this regimen is suggested at least in heavily pretreated patients.
摘要
丝裂霉素加长春地辛已被用作一线化疗难治的转移性乳腺癌患者的挽救治疗。在15例可连续评估的患者中未观察到反应；根据Gehan检验，至少在经过大量预处理的患者中提示该方案缺乏有效性。
相似文献
1
Failure of mitomycin-vindesine combination chemotherapy as salvage treatment for metastatic breast cancer.丝裂霉素-长春地辛联合化疗作为转移性乳腺癌挽救治疗的失败情况。
J Cancer Res Clin Oncol. 1985;110(1):77-8. doi: 10.1007/BF00402506.
2
Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer.丝裂霉素C、长春地辛和美法仑联合化疗治疗难治性转移性乳腺癌。
J Cancer Res Clin Oncol. 1991;117(3):266-8. doi: 10.1007/BF01625437.
3
Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine.
J Clin Oncol. 1983 Dec;1(12):772-5. doi: 10.1200/JCO.1983.1.12.772.
4
Dyspnea following vinblastine or vindesine administration in patients receiving mitomycin plus vinca alkaloid combination therapy.
Cancer Treat Rep. 1984 Jul-Aug;68(7-8):1029-31.
5
First-line and salvage therapy of metastatic breast cancer with mitomycin/vinblastine.
Oncology. 1993 Apr;50 Suppl 1:16-21. doi: 10.1159/000227243.
6
[Salvage chemotherapy with mitomycin C and vindesine in metastatic carcinoma of the breast].[丝裂霉素C与长春地辛用于乳腺癌转移的挽救性化疗]
G Ital Chemioter. 1985 Jan-Apr;32(1):61-2.
7
Vindesine and mitomycin C in chemotherapy: refractory advanced breast cancer.长春地辛与丝裂霉素C用于化疗：难治性晚期乳腺癌
Cancer. 1986 Mar 1;57(5):904-7. doi: 10.1002/1097-0142(19860301)57:5<904::aid-cncr2820570503>3.0.co;2-4.
8
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
9
10
Salvage therapy for metastatic disease.转移性疾病的挽救治疗。
Semin Oncol. 1990 Aug;17(4 Suppl 7):45-9.
本文引用的文献
1
The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent.一种新型化疗药物的初步试验和后续试验所需患者数量的确定。
J Chronic Dis. 1961 Apr;13:346-53. doi: 10.1016/0021-9681(61)90060-1.
2
Reporting results of cancer treatment.癌症治疗结果报告。
Cancer. 1981 Jan 1;47(1):207-14. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6.
3
Phase II study of vindesine in patients with metastatic breast cancer.
Cancer Treat Rep. 1981 Jul-Aug;65(7-8):659-63.
4
A phase II study of Mitomycin C in refractory adcvanced breast cancer. A multi-centre pilot study.丝裂霉素C治疗难治性晚期乳腺癌的II期研究。一项多中心试点研究。
Eur J Cancer (1965). 1980;Suppl 1:275-6.
5
Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine.
J Clin Oncol. 1983 Dec;1(12):772-5. doi: 10.1200/JCO.1983.1.12.772.
6
Chemotherapy of breast cancer.乳腺癌的化疗
Med Oncol Tumor Pharmacother. 1984;1(3):169-92. doi: 10.1007/BF02934139.
Zotero 插件